Notably, off-label tenecteplase had already become the preferred thrombolytic for acute ischemic stroke before the expanded ...

Genentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.

Genentech has had the lone medicine on the market for the acute treatment of stroke. | Over nearly the last three decades, ...

The approval is based on results of the AcT trial, where tenecteplase was comparable to alteplase for safety and efficacy.

According to Roche subsidiary Genentech, which announced the label expansion on Monday, TNKase is the first new drug for ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug ...

In 2023, Roche said it was removing TNKase for stroke from its phase 3 programmes after a readout of the TIMELESS trial, but ...

Genentech, part of the Roche (ROG SIX) group, has received a new approval from the US Food and Drug Administration for TNKase ...

Genentech announced that the U.S. Food and Drug Administration has approved TNKase, a thrombolytic or clot-dissolving agent, for the treatment ...

The approval was supported by data from the registry-linked, parallel group, open-label, randomized AcT trial, which compared tenecteplase to alteplase.

A major shift in stroke care is underway as tenecteplase outperforms alteplase. This new treatment could redefine recovery ...

Genentech, a member of the Roche Group, announced that the FDA has approved the company’s TNKase (tenecteplase) thrombolytic ...